Fluorouracil

Generic Name: Fluorouracil

Brand Names: Actikerall, Carac, Efudex, Fluoroplex, Tolak

Drug Type: Small Molecule

Chemical Formula: C_₄H_₃FN_₂O_₂

CAS Number: 51-21-8

Unique Ingredient Identifier: U3P01618RT

Background: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.

Indication: For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.

Associated Conditions: Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis

Associated Therapies: -

Clinical Trials

Irofulven Compared With Fluorouracil in Treating Patients With Pancreatic Cancer

Phase 3

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: Irofulven
Drug: fluorouracil

First Posted Date: 2004-01-15

Last Posted Date: 2012-12-24

Lead Sponsor: Eisai Inc.

Target Recruit Count: 158

Registration Number: NCT00033735

Locations: 🇺🇸
MGI Pharma, Incorporated, Bloomington, Minnesota, United States

Fluorouracil, Irinotecan, Leucovorin, and Cisplatin as First-Line Therapy in Treating Patients With Metastatic Esophageal Cancer

Phase 2

Conditions: Esophageal Cancer

First Posted Date: 2004-01-13

Last Posted Date: 2008-07-24

Lead Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group

Registration Number: NCT00075738

Locations: 🇫🇷
Clinique La Casamance, Abugne, France
🇫🇷
Hopital Drevon, Dijon, France
🇫🇷
Centre Jean Bernard, Le Mans, France

and more 12 locations

Fluorouracil, Leucovorin, and Irinotecan in Treating Patients With Recurrent or Refractory Metastatic Unresectable Colorectal Cancer

Phase 2

Conditions: Colorectal Cancer

First Posted Date: 2004-01-12

Last Posted Date: 2009-01-06

Lead Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group

Registration Number: NCT00075595

Locations: 🇫🇷
Polyclinique De Courlancy, Reims, France
🇫🇷
Clinique Armoricaine De Radiologie, Saint Brieuc, France
🇫🇷
Clinique Saint Jean, Lyon, France

and more 12 locations

Vaccine Therapy Plus Chemotherapy in Treating Patients With Metastatic or Locally Recurrent Stomach Cancer or Esophageal Cancer

Phase 3

Completed

Conditions: Gastric Cancer
Esophageal Cancer

Interventions: Biological: G17DT Immunogen
Drug: cisplatin
Drug: fluorouracil

First Posted Date: 2004-01-08

Last Posted Date: 2020-08-03

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 8

Registration Number: NCT00020787

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

Fluorouracil and Leucovorin With or Without Oxaliplatin in Treating Patients With Recurrent Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer

First Posted Date: 2004-01-07

Last Posted Date: 2013-06-26

Lead Sponsor: Prologue Research International

Registration Number: NCT00016198

Locations: 🇺🇸
South Shore Hematology Oncology Associates, P.C., Rockville Centre, New York, United States
🇺🇸
Center for Hematology-Oncology, Boca Raton, Florida, United States
🇺🇸
Pennsylvania Oncology Hematology Associates, Philadelphia, Pennsylvania, United States

and more 70 locations

Combination Chemotherapy in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer

Phase 2

Completed

Conditions: Liver Cancer
Extrahepatic Bile Duct Cancer
Gallbladder Cancer

Interventions: Drug: fluorouracil
Drug: gemcitabine hydrochloride
Drug: leucovorin calcium

First Posted Date: 2004-01-01

Last Posted Date: 2016-12-07

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 42

Registration Number: NCT00009893

Locations: 🇺🇸
CCOP - Carle Cancer Center, Urbana, Illinois, United States
🇺🇸
Siouxland Hematology-Oncology, Sioux City, Iowa, United States
🇺🇸
Medcenter One Health System, Bismarck, North Dakota, United States

and more 16 locations

Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: fluorouracil
Drug: gemcitabine hydrochloride
Drug: oxaliplatin

First Posted Date: 2003-12-11

Last Posted Date: 2013-02-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT00004242

Locations: 🇺🇸
NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York, New York, United States
🇺🇸
Albert Einstein Comprehensive Cancer Center, Bronx, New York, United States